// App-Quantinova.ai

P488 : Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan®

Researchers

Presenter

  • Raine, T

Principal Investigators

  • Melmed, G.Y

  • Finney-Hayward , T

  • Clark, R

  • Chapman, J.C

  • Targownik, L

  • Burisch, J

  • Olen, O

Medical Centers

  • Addenbrookes Hospital - Cambridge University Hospitals NHS FT, Gastroenterology, Cambridge, United Kingdom

  • Cedars-Sinai, Inflammatory Bowel Disease Center, Los Angeles, United States

  • AbbVie Ltd., Gastroenterology, Maidenhead, United Kingdom

  • AbbVie Inc, Research and Development, North Chicago, United States

  • Texas Digestive Disease Consultants, Gastroenterology, Baton Rouge, United States

  • Mount Sinai Hospital, University of Toronto, Division of Gastroenterology, Toronto, Canada

  • Hvidovre University Hospital, Gastrounit, Medical section, Hvidovre, Denmark

  • Karolinska Institutet, Department of medicine, Stockholm, Sweden

Locations

  • United Kingdom

  • United States

  • Canada

  • Denmark

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

Biomarkers

  • N/A

Drug/Treatment

  • Methylprednisolone

  • Budesonide

  • Prednisone

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved